American Century Companies Inc. Buys 29,489 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

American Century Companies Inc. raised its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 99.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,149 shares of the company’s stock after acquiring an additional 29,489 shares during the period. American Century Companies Inc. owned approximately 0.11% of Stoke Therapeutics worth $799,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Quest Partners LLC bought a new stake in shares of Stoke Therapeutics during the second quarter worth about $29,000. Nisa Investment Advisors LLC increased its holdings in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics during the first quarter valued at about $141,000. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after acquiring an additional 6,636 shares during the last quarter.

Stoke Therapeutics Trading Up 0.7 %

NASDAQ STOK opened at $12.37 on Wednesday. The stock has a market cap of $644.74 million, a price-to-earnings ratio of -5.13 and a beta of 0.96. Stoke Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $17.58. The company’s 50 day moving average is $14.26 and its two-hundred day moving average is $13.48.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on STOK shares. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.40.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.